Top French (CAC) Growth Stocks

Top French (CAC) Growth Stocks

UPDATED Jun 29, 2022

What are the best French (CAC) Growth Stocks?

According to our Simply Wall St analysis these are the best French growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

10 companies meet this criteria in the French market

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: ALVAL is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 96.5% below our estimate of its fair value

  • Earnings are forecast to grow 100.72% per year

Risks

  • Makes less than USD$1m in revenue (€298K)

  • Does not have a meaningful market cap (€60M)

View all Risks and Rewards

Balyo SA designs, develops, and markets material handling robots worldwide.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: BALYO is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Earnings are forecast to grow 76.13% per year

  • Earnings have grown 8.1% per year over the past 5 years

Risks

  • Does not have a meaningful market cap (€28M)

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Kaufman & Broad S.A. operates as a property developer and builder in France.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: KOF's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Trading at 75.6% below our estimate of its fair value

  • Earnings are forecast to grow 25.1% per year

Risks

No risks detected for KOF from our risks checks.

View all Risks and Rewards

AURES Technologies S.A. designs, manufactures, and sells point of sale (POS) systems and terminals, and related peripherals.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: AURS's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Trading at 60.9% below our estimate of its fair value

  • Earnings are forecast to grow 60.93% per year

Risks

  • Does not have a meaningful market cap (€60M)

View all Risks and Rewards

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: VLA is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Earnings are forecast to grow 80.54% per year

Risks

  • Highly volatile share price over the past 3 months

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Aelis Farma S.A., a clinical-stage biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of unaddressed central nervous system disorders.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: AELIS's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 49.6% below our estimate of its fair value

  • Earnings are forecast to grow 58.19% per year

  • Became profitable this year

Risks

No risks detected for AELIS from our risks checks.

View all Risks and Rewards

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: ALQGC is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 99.9% below our estimate of its fair value

  • Earnings are forecast to grow 71.85% per year

Risks

  • Does not have a meaningful market cap (€66M)

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

View all Risks and Rewards

Claranova SE engages in the internet, mobile, and internet of things businesses in the Unites States, the United Kingdom, Germany, France, India, other European countries, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CLA's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • Future ROE

  • High Growth Revenue

See Full Stock Report

Rewards

  • Trading at 59.2% below our estimate of its fair value

  • Earnings are forecast to grow 56.62% per year

Risks

  • Shareholders have been diluted in the past year

  • Profit margins (1%) are lower than last year (1.7%)

  • Large one-off items impacting financial results

  • Volatile share price over the past 3 months

View all Risks and Rewards
Page 1 of 2